R

Respiri Ltd
ASX:RSH

Watchlist Manager
Respiri Ltd
ASX:RSH
Watchlist
Price: 0.076 AUD -2.56% Market Closed
Market Cap: 100.8m AUD
Have any thoughts about
Respiri Ltd?
Write Note
RSH
/
Income Statement
/
Revenue

Respiri Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Respiri Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
R
Respiri Ltd
ASX:RSH
Revenue
AU$1m
CAGR 3-Years
-10%
CAGR 5-Years
0%
CAGR 10-Years
14%
ImpediMed Ltd
ASX:IPD
Revenue
AU$10.3m
CAGR 3-Years
7%
CAGR 5-Years
20%
CAGR 10-Years
11%
C
Cyclopharm Ltd
ASX:CYC
Revenue
AU$29m
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
8%
Cochlear Ltd
ASX:COH
Revenue
AU$2.2B
CAGR 3-Years
14%
CAGR 5-Years
9%
CAGR 10-Years
11%
Optiscan Imaging Ltd
ASX:OIL
Revenue
AU$1.2m
CAGR 3-Years
9%
CAGR 5-Years
2%
CAGR 10-Years
29%
EMvision Medical Devices Ltd
ASX:EMV
Revenue
AU$11.6m
CAGR 3-Years
182%
CAGR 5-Years
59%
CAGR 10-Years
N/A
No Stocks Found

Respiri Ltd
Glance View

Market Cap
100.8m AUD
Industry
Health Care

Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-07-14. The firm's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The firm has developed a wheezo, which is an eHealth Saas platform that uses a device and app to measure, record and assist asthma monitoring. Its device and app make up a cloud-based mobile health platform that records wheeze and other clinically relevant symptoms and signs of asthma.

RSH Intrinsic Value
0.008 AUD
Overvaluation 90%
Intrinsic Value
Price
R
What is Intrinsic Value?

See Also

What is Respiri Ltd's Revenue?
Revenue
1m AUD

Based on the financial report for Jun 30, 2024, Respiri Ltd's Revenue amounts to 1m AUD.

What is Respiri Ltd's Revenue growth rate?
Revenue CAGR 10Y
14%

Over the last year, the Revenue growth was 57%. The average annual Revenue growth rates for Respiri Ltd have been -10% over the past three years , and 14% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 211,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.